Durvalumab (Imfinzi) in combination with gemcitabine and cisplatin is now also indicated as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with muscle invasive bladder cancer.
Normal immunoglobulin (human) and vorhyaluronidase alfa (Hyqvia) is now also indicated in children 2 years of age and older for replacement therapy in primary immunodeficiency disease and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment, and in adults and children 2 years of age and older for immunomodulatory therapy in chronic inflammatory demyelinating polyneuropathy, as maintenance therapy after stabilisation with intravenous immunoglobulin.
Selpercatinib (Retevmo) is now indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic rearranged during transfection-mutant medullary thyroid cancer who require systemic therapy.
Trastuzumab deruxtecan (Enhertu) is now indicated (with provisional approval) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumours have activating human epidermal growth factor receptor 2 (erythroblastic oncogene B 2) mutations and who have received prior platinum-based chemotherapy with or without immunotherapy.
New Contraindications
Phenobarbital (Phenobarb)is now contraindicated in patients with a natural or acquired idiosyncrasy to barbiturates.
Voriconazole (Vfend) is now contraindicated for concomitant use with medicinal products that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions (including eplerenone and voclosporin) and with medicinal products that induce CYP3A4 and significantly reduce plasma concentrations of voriconazole.
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.
To contact MIMS editorial please email editorial@mims.com.au. To enquire about purchasing a product please contact MIMS Customer service on 1800 800 629 or email subscriptions@mims.com.au. For more information about MIMS, please see www.mims.com.au.
